<DOC>
	<DOC>NCT01973894</DOC>
	<brief_summary>This study investigates what independent variables may influence Midazolam Pharmacokinetics in critically ill patients.</brief_summary>
	<brief_title>Midazolam Whole Body Physiologically Based Pharmacokinetic Model</brief_title>
	<detailed_description>This study has three specific aims: 1. to create a Midazolam PBPK model based on anthropometric and physiopathological data from enrolled patients; 2. to estimate cerebral and systemic Midazolam concentrations; 3. to assess independent variables about Midazolam pharmacokinetic in critically ill patients.</detailed_description>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>ICU admittance Caucasian Clinical indication of least 72h of continuous sedation with Midazolam MAP between 60 150 mmHg, even if obtained with amine support informed consent obtained Any endocranial lesion, spontaneous or induced PaCO2 &gt; 60 mmHg or &lt; 30 mmHg PaO2 &lt; 50 mmHg Pregnancy Anuria Any transplantation Severe hepatic failure (Child C) Life expectancy &lt; 72h Ketoconazole and antiretrovirals in therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>PBPK</keyword>
	<keyword>Midazolam</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Critically ill patients</keyword>
</DOC>